Congrats #MiraeAsset on making the Endpoints Top 100 Venture Investors in Biotech list for 2024! We are excited to invest more in 2025! Mirae Asset Capital Life Science #MiraeAssetCapital Thomas Suter, PhD David T. Paik https://lnkd.in/dK98Us9S
关于我们
Mirae Asset Capital Life Science is the first and only U.S. affiliate of Mirae Asset Financial Group dedicated to life science investment. We invest in companies prioritizing the delivery of safe and effective treatments for patients who need it most and believe that superior returns will follow. Our strategy is rooted in core principles that include delivering near-term value, calculated risk, finding innovative yet validated modalities, and rigorous evaluation using our unique backgrounds that span biomedical research, drug discovery, company building, clinical/medical training, and venture capital experience. Mirae Asset Capital Life Science spans the major hubs of life science innovation domestically. Our investment team is located in Boston and San Francisco, and our legal and administrative teams are based in New York.
- 网站
-
lifesci.miraeasset.com
Mirae Asset Capital Life Science的外部链接
- 所属行业
- 风险投资与私募股权管理人
- 规模
- 2-10 人
- 总部
- New York，NY
- 类型
- 私人持股
- 创立
- 2023
- 领域
- Biotech和Venture Capital
地点
Mirae Asset Capital Life Science员工
动态
-
Please tune in to see our Managing Director, Naveen Krishnan, on the BioVerse Episode 17 - JPM2025 Recap - News, Trends, Sentiment, and China Trade below! Mirae Asset Capital Life Science #MiraeAsset David T. Paik Thomas Suter, PhD Link to replay: https://lnkd.in/d9cERvnR
Join us for an exclusive webinar where we will summarize the major news, trends, and sentiment from the J.P. Morgan Morgan #Healthcare Conference 2025 #JPM25. This event will feature industry veterans Fay Xing, MD from Panacea Venture, Biren Amin from Piper Sandler, Weiyong Sun from Jiangsu Hansoh Pharmaceutical Group Co., Ltd., and Naveen Krishnan from Mirae Asset Capital Life Science who will share their observations and insights on the global biotech and pharmaceutical capital market.
此处无法显示此内容
在领英 APP 中访问此内容等
-
We are thrilled to announce that Thomas Suter, PhD is joining our investment team at Mirae Asset Capital Life Science as an Associate in our Boston office. Tom received his PhD from UC San Diego and brings over 3 years of industry experience. Please join us in welcoming Tom to the #MiraeAsset family and find him at #JPM25 in San Francisco! Mirae Asset Capital Life Science Mirae Asset Global Investments Mirae Asset Capital Naveen Krishnan David T. Paik Thomas Suter, PhD
-
-
Our portfolio company Accent Therapeutics, Inc. has dosed the first patient with the first-in-class oral DHX9 inhibitor ATX-559 in its Phase 1/2 trial. To learn more about Accent's discovery and development of DHX9 inhibitor, take a look at a recent publication from Accent Therapeutics, Inc. here: https://lnkd.in/g8VZuz6u Naveen Krishnan David T. Paik Mirae Asset Capital Life Science Mirae Asset Capital #DHX9 #PrecisionOncology #AccentTherapeutics #MSI #dMMR
?? NEWS: The first patient has been dosed in Accent’s Phase 1/2 trial of ATX-559, our first-in-class oral DHX9 inhibitor! Learn more: https://bit.ly/41nQrkR #cancerresearch #drugdevelopment #DHX9 #clinicaltrial #breastcancer #colorectalcancer
-
-
Exciting news from our portfolio company Accent Therapeutics, Inc. on receiving IND clearance for ATX-559, a first-in-class oral #DHX9 inhibitor. ATX-559 Phase 1/2 trial (NCT06625515) will focus on patients with BRCA1/2-deficient breast cancer and MSI-H and/or dMMR cancers to evaluate safety, tolerability, PK/PD, and preliminary efficacy of ATX-559. Press release: https://lnkd.in/gXQQVKXV Mirae Asset Capital Life Science and the affiliates are pleased to support Shakti Narayan and the Accent team in making this breakthrough in developing and advancing a first-in-class DHX9 inhibitor and pushing the boundaries in #PrecisionOncology. Naveen Krishnan David Paik Daniel Kwon Ray Hyo Won Ahn Hansoo Kim Mirae Asset Capital #DHX9 #breastcancer #MSIhigh #dMMR #KIF18A #Oncology #AccentTherapeutics #biotech
???NEWS: The FDA has cleared our Investigational New Drug (IND) application for ATX-559, our first-in-class oral DHX9 inhibitor, paving the way for a Phase 1/2 trial focused on patients with BRCA1/2-deficient breast cancer and solid tumors with microsatellite instability and/or deficient mismatch repair (NCT06625515). Learn more: https://bit.ly/40bAbmq #cancerresearch #drugdevelopment #DHX9 #clinicaltrial #breastcancer #colorectalcancer
-
-
Excited to work with you, the other investors, Ken, and the Candid team to bring therapies to patients!
Very pleased to support Ken Song and the team at?Candid Therapeutics! Candid announced its launch today to focus on developing antibody drugs for inflammatory diseases. As part of the launch, Candid has acquired the Foresite Labs-incubated company Vignette Bio and its T-cell engagers; the team will start clinical trials in autoimmunity next year. Our managing director Michael Rome will be joining the board.?We look forward to working closely with this team.
-
We are proud to invest alongside this top-tier group of investors, humbled to see the over $370M of capital that has come into the company, and excited to work this stellar management team led by Ken Song to advance bispecific T-cell engager antibodies as treatments for autoimmune diseases as part of Candid Therapeutics! Naveen Krishnan, David T. Paik, #MiraeAsset #MiraeAssetCapitalLifeScience
Shortly after leading radiopharma startup RayzeBio to a $4B+ exit to Bristol Myers Squibb earlier this year, Ken Song hit the ground running for his next bet. He set up a shell company in the spring and went on a hunt for clinical-stage drugs. He looked at nearly 50 opportunities across pain, oncology and other disease areas before quickly settling on the potential of T cell engagers for autoimmune diseases. He assembled more than $370 million in funds for his new company, Candid Therapeutics, and acquired two biotech startups: Vignette Bio and TRC 2004. Both had inked licensing deals in recent months for clinical-stage medicines out of China-based drug developers. I spoke with Song about Candid, raising one of the year's largest private biotech financing rounds, the potential of T cell engagers in autoimmune and more for Endpoints News: #autoimmunediseases #autoimmunedrugs #tcellengagers #celltherapy #biotech #candidtherapeutics #venturecapital
-
We are thrilled to announce our second investment in Vignette Bio after sourcing EMB-06 (BCMA x CD3 T-cell engager) from EpimAb Biotherapeutics, Inc. (Mirae Asset portfolio company), and bringing it to Foresite Capital. We look forward to working with Foresite Capital, Qiming Venture Partners, Qiming Venture Partners USA, and Samsara Biocapital to try to revolutionize the treatment of autoimmune disease with bispecific T-cell engagers. We will continue to look for valuable assets globally across our core sectors utilizing our strong global network, please reach out to us at [email protected] if you are interested in discussing further. Please stay tuned for more exciting announcements in the coming weeks! Naveen Krishnan, David T. Paik, #MiraeAssetCapitalLifeScience #MiraeAssetCapital, #MiraeAsset, #VignetteBio, #ForesiteCapital, #Qiming, #Samsara, #Epimab, #bispecifics, #TCEs, #autoimmunedisease, #immunereset https://lnkd.in/dTyCQxfb
-
Please note our Associate/Sr. Associate job posting is back to being active, if you are interested please apply below! https://lnkd.in/ePEEzFa8 #miraeasset #lifescience #biotech Naveen Krishnan David T. Paik
-
We are hiring an Associate/Sr. Associate to join our investment team in Boston! If you are passionate about life science and interested in venture capital please apply! Please check out more info below and on our website (www.lifesci.miraeasset.com). #lifescience #venturecapital #miraeasset Naveen Krishnan David T. Paik Mirae Asset Global Investments https://lnkd.in/ePEEzFa8